The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy [Corrigendum]

Yang M, Qin X, Qin G, Zheng X. *Onco Targets Ther.* 2019;12:2171–2180.

platinum (TP); Platinum + cyclophosphamide (TC) should have been Docetaxel + cyclophosphamide (TC).

On page 2172, Chemotherapy regimens section in Table 1, Platinum + platinum (TP) should have been Docetaxel +

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>